Jpmorgan Chase & CO Cyclo Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 193 shares of CYTH stock, worth $177. This represents 0.0% of its overall portfolio holdings.
Number of Shares
193
Previous 194
0.52%
Holding current value
$177
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CYTH
# of Institutions
21Shares Held
2.24MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA689KShares$634,2910.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA599KShares$550,7980.0% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$442,25116.84% of portfolio
-
Geode Capital Management, LLC Boston, MA152KShares$140,1450.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$101,221100.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $7.76M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...